Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non–Small-Cell Lung Cancer

Author:

Pöttgen Christoph1,Gauler Thomas1,Bellendorf Alexander1,Guberina Maja1,Bockisch Andreas1,Schwenzer Nina1,Heinzelmann Frank1,Cordes Sebastian1,Schuler Martin H.1,Welter Stefan1,Stamatis Georgios1,Friedel Godehard1,Darwiche Kaid1,Jöckel Karl-Heinz1,Eberhardt Wilfried1,Stuschke Martin1

Affiliation:

1. Christoph Pöttgen, Thomas Gauler, Alexander Bellendorf, Maja Guberina, Andreas Bockisch, Sebastian Cordes, Martin H. Schuler, Karl-Heinz Jöckel, Wilfried Eberhardt, and Martin Stuschke, University Hospital Essen; University of Duisburg-Essen; Stefan Welter, Georgios Stamatis, and Kaid Darwiche, Ruhrlandklinik, Essen; Nina Schwenzer and Frank Heinzelmann, University Hospital Tübingen; University of Tübingen, Tübingen; and Godehard Friedel, Robert-Bosch-Krankenhaus; Klinikum Schillerhöhe, Gerlingen, Germany.

Abstract

Purpose A confirmatory analysis was performed to determine the prognostic value of metabolic response during induction chemotherapy followed by bimodality/trimodality treatment of patients with operable locally advanced non–small-cell lung cancer. Patients and Methods Patients with potentially operable stage IIIA(N2) or selected stage IIIB non–small-cell lung cancer received three cycles of cisplatin/paclitaxel (induction chemotherapy) followed by neoadjuvant radiochemotherapy (RCT) to 45 Gy (1.5 Gy twice per day concurrent cisplatin/vinorelbine) within the ESPATUE (Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA[N2] and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy) trial. Positron emission tomography scans were recommended before (t0) and after (t2) induction chemotherapy. Patients who were eligible for surgery after neoadjuvant RCT were randomly assigned to definitive RCT or surgery. The prognostic value of percentage of maximum standardized uptake value (%SUVmax) remaining in the primary tumor after induction chemotherapy—%SUVremaining = SUVmax(t2)/SUVmax(t0)—was assessed by proportional hazard analysis and receiver operating characteristic analysis. Results Overall, 161 patients were randomly assigned (155 from the Essen and Tübingen centers), and 124 of these received positron emission tomography scans at t0 and t2. %SUVremaining as a continuous variable was prognostic for the three end points of overall survival, progression-free survival, and freedom from extracerebral progression in univariable and multivariable analysis (P < .016). The respective hazard ratios per 50% increase in %SUVremaining from multivariable analysis were 2.3 (95% CI, 1.5 to 3.4; P < .001), 1.8 (95% CI, 1.3 to 2.5; P < .001), and 1.8 (95% CI, 1.2 to 2.7; P = .006) for the three end points. %SUVremaining dichotomized at a cut point of maximum sum of sensitivity and specificity from receiver operating characteristic analysis at 36 months was also prognostic. Exploratory analysis revealed that %SUVremaining was likewise prognostic for overall survival in both treatment arms and was more closely associated with extracerebral distant metastases (P = .016) than with isolated locoregional relapses (P = .97). Conclusion %SUVremaining is a predictor for survival and other end points after multimodality treatment and can serve as a parameter for treatment stratification after induction chemotherapy or for evaluation of adjuvant new systemic treatment options for high-risk patients.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3